At the 2022 ASCO annual meeting, Matthew Goetz, MD, Mayo Clinic, Rochester, MN, discusses recent research presented at the 2022 ASCO annual meeting related to therapeutic options for breast cancer. Dr Goetz discusses CDK4/6 inhibitors and options for patients following progression on a CDK4/6 inhibitor.
More Videos in Metastatic Breast Cancer Content Hub
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Polly Niravath, MD, breast oncologist, Houston Methodist Cancer Center, Texas, discusses breast to brain metastasis. Dr Nirvath also reviews some available medications to treat brain metastases in patients…
Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
In this video, Sarah DiGeronimo, NP, and Sydney Smith, PharmD, both from Dana-Farber Cancer Institute, Boston, Massachusetts, discuss tips for the management of common side effects resulting from…
Angela Belcher, PhD; Sangeeta Bhatia, MD, PhD; and Paula Hammond, PhD, from the Koch Institute at MIT, Cambridge, MA, present multi-dimensional approaches to early detection in ovarian cancer.…
Approximately 30% of women with early-stage breast cancer will face metastatic disease, and 6% are diagnosed with metastatic breast cancer initially. Living with metastatic breast cancer can elicit…
Javier Cortés, MD, PhD, head of the International Breast Cancer Centre (IBCC), Barcelona, Spain, reviews subgroup analyses from the Phase 3 EMERALD trial. Professor Cortés discusses how these…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
Tufia C. Haddad, MD, an oncologist at Mayo Clinic, Rochester, Minnesota, discusses what to expect before, during, and after initial treatment for metastatic breast cancer. Dr Haddad emphasizes…